The GLP is committed to full transparency. Download and review our Annual Report.

FDA rejects call for USDA takeover of CRISPR gene-edited animal regulation

| | July 9, 2019

The Food and Drug Administration is standing its ground in the latest battle over its regulatory turf, warning livestock groups it has no intention of relinquishing its authority to oversee biotech animals.

Livestock groups have stepped up calls for the Agriculture Department to be given an expanded role in regulating the burgeoning technology, but FDA officials have made clear they will resist efforts to get it to cede control over the approval process for biotech animals. Agency officials told POLITICO that Congress has empowered FDA to regulate biotech animals and USDA to review genetically engineered plants — a system that FDA officials believe plays to each department’s strengths.

Related article:  'Don’t try this at home': New California law targets biohacking, do-it-yourself CRISPR

“We each have different, respective roles based off our statutory frameworks,” said Steven Solomon, director of FDA’s Center for Veterinary Medicine.

[C]ritics have organized a public campaign, led by the National Pork Producers Council, to raise support for USDA to be given jurisdiction over biotech animals.

Critics complain FDA’s framework is too cumbersome …. They point to the fact FDA to date has approved only one biotech animal intended for human consumption, in a review that spanned two decades.

Read full, original article: FDA defends its regulatory prowess in debate over biotech animals (Behind Paywall)

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend